Slapping back at Allergan plc, a venture capital fund is defending its right to try to invalidate the drugmaker's remaining patent on a glaucoma drug by taking advantage of the lower "patent-killing" standard of an inter partes review (IPR) before the Patent Trial and Appeals Board (PTAB).